Inmune Bio’s Promising Future: Buy Rating Backed by Key Data Releases and Innovative Approaches

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), retaining the price target of $30.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Inmune Bio’s promising future prospects. The company has several key data releases scheduled for 2025, including the Phase 2 data for XPro in Alzheimer’s disease and the Phase 1/2 data update for INKmune in metastatic castration-resistant prostate cancer. These milestones are expected to provide significant insights into the effectiveness of their treatments, potentially driving the stock’s value upward.
Additionally, Inmune Bio’s financial position appears stable, with sufficient cash reserves to support its operations through the second half of 2025. The company’s innovative approach, such as using the Early Mild Alzheimer’s Cognitive Composite as a primary endpoint in their Alzheimer’s study, could redefine treatment evaluation in this field. Moreover, the underappreciated potential of their CORDstrom cell therapy program in regenerative medicine presents an opportunity for additional upside, making the stock an attractive buy.

In another report released yesterday, Raymond James also reiterated a Buy rating on the stock with a $23.00 price target.

INMB’s price has also changed dramatically for the past six months – from $5.390 to $7.810, which is a 44.90% increase.